Nouscom secures funding for cancer immunotherapy trials
The biotechnology enterprise based in Basel gathered financial backing to progress clinical testing of its novel medical treatments.
Editorial team Replicable · · Source: EU-Startups
Nouscom closed a financing round totalling €120 million to support the development of its investigational cancer treatment. The funding effort received backing from multiple investment organisations, including M Ventures and Revelation Partners.